Eisai, U.S.-Based SuperGen Hit Setback For Leukemia Drug
This article was originally published in PharmAsia News
Eisai's effort to develop a leukemia drug in the United States suffered a setback when its U.S. partner, SuperGen, reported the drug failed to meet clinical trial endpoints
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.